These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 3164959)

  • 1. [On the problem of the cardiotoxicity of epirubicin-cisplatin].
    Lechner W; Zechmann W; Mayr P; Reider W; Marth C
    Zentralbl Gynakol; 1988; 110(7):429-32. PubMed ID: 3164959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin.
    de Bree E; van Ruth S; Schotborgh CE; Baas P; Zoetmulder FA
    Ann Surg Oncol; 2007 Oct; 14(10):3019-26. PubMed ID: 17638057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography.
    Pichon MF; Cvitkovic F; Hacene K; Delaunay J; Lokiec F; Collignon MA; Pecking AP
    In Vivo; 2005; 19(3):567-76. PubMed ID: 15875778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
    Sparano JA
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.
    Ding S; Xiong S; Wang X; Zhang C; Chen S; Sun M; Wu C; Zhang X; Wang M; Wang J; Shang X
    Clin Transl Oncol; 2024 Jun; 26(6):1459-1466. PubMed ID: 38329609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.
    Torti FM; Bristow MM; Lum BL; Carter SK; Howes AE; Aston DA; Brown BW; Hannigan JF; Meyers FJ; Mitchell EP
    Cancer Res; 1986 Jul; 46(7):3722-7. PubMed ID: 3458531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
    Gershanovich ML; Moiceenko VM; Orlova RV
    Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serial determination of anthracycline poisoning in children].
    Stein JI; Langevin A; Benson LN; Souza MD; Wilson G; Chan H
    Wien Klin Wochenschr; 1989 Jan; 101(1):45-8. PubMed ID: 2913725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity.
    Martin M; Lluch A; Ojeda B; Barnabas A; Colomer R; Massuti B; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-26-S17-30. PubMed ID: 9374088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is the use of adriamycin (doxorubicin) limited by its cardiotoxicity?].
    Reinhardt D; Hofmann V; Martz G
    Schweiz Med Wochenschr; 1985 Apr; 115(16):557-61. PubMed ID: 4001904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy with high dose of anthracyclines combined with cisplatin in the treatment of soft tissue sarcomas].
    Jelić S; Milanović N; Kovcin V; Tomasević Z; Vuletić L
    Srp Arh Celok Lek; 1994; 122(9-10):265-8. PubMed ID: 17977432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
    Cantore M; Mambrini A; Fiorentini G; Rabbi C; Zamagni D; Caudana R; Pennucci C; Sanguinetti F; Lombardi M; Nicoli N
    Cancer; 2005 Apr; 103(7):1402-7. PubMed ID: 15726542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of soft tissue sarcomas in the adult with a combination of vindesine and cisplatin with doxorubicin or epirubicin: a pilot study].
    Becouarn Y; Bui BN; Kerbrat P; Chauvergne J; Brunet R; Robert J
    Bull Cancer; 1987; 74(2):109-16. PubMed ID: 3475140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.